Oragenics Inc. · AMEX:OGEN
Oragenics — Investor Presentation (November 2021)
21 slides from Oragenics's investor presentation, Nov 12, 2021
Slide 1: Corporate Presentation
Developing Vaccines & Novel Antibiotics | - «to Prevent & Treat ‘Today's & Tomorrow's Infections: Corporate Presentation
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements made in this presentation include forward-looking actions that Oragenics, Inc. ("Oragenics,’ or the “Company’) anticipates based on certain assumptions. These statements are indicated by words such as “expect”, “anticipate”, “should” and similar words in
Slide 3: Agenda
Agenda ¢ Introduction — Dr. Fred Telling, Executive Chair + COVID-19 Vaccine Commercial Analysis & Terra CoV-2 Opportunity — Dr. Timothy Cooke, Commercial Consultant * Terra CoV-2 Development Status — Terrence Cochrane, CMC Consultant * Corporate Status Update — Michael Sullivan, Interim Principal E
Slide 4: Corporate Overview
Corporate Overview Oragenics is a development-stage company dedicated to fighting infectious diseases, including coronaviruses and multidrug-resistant organisms Lead product is Terra CoV-2, a vaccine candidate to prevent COVID-19 * Gained access to multiple enabling technologies * Focusing on intran
Slide 5: Investment Highlights
Investment Highlights al ae
Slide 6: COVID-19 Vaccine Commercial Analysis & Terra CoV-2 Opportunity
covip- 19 Vaccine Commercial analy Zi Terra CoV-2 Opportunity
Slide 7: COVID-19 Vaccine Commercial Analysis
COVID-19. Vaccine Commercial Analysis * Market evolving rapidly across several dimensions — Virus evolution with emergence & disappearance of variants — Target populations are increasingly “seropositive” (from vaccination or exposure) — Rapidly shifting competitive landscape * Terra CoV-2 commercial
Slide 8: Rapid global evolution of variants
COVID-19. Vaccine Commercial Analysis Rapid global evolution of variants Global SARS-CoV-2 Strain Distribution 100% 80% 4 60% 4 40% 4 20% 4 Alpha Gamma 21A (Delta) 96% of global v: Delta reported to bi ints QF T 2020-Oct 2021-Feb T 2020-Dec Data from nextstrain.org/ncov/gisaid/global, accessed 10/6/
Slide 9: Share of people vaccinated against COVID-19
Share of people ve ated against COVID-19, Nov 5, 2021 Alternative defnitions of a full vaccination, eg, having been infected with SARS-CoV-2 and having 1 dose ofa 2-dose protocol, are ignored to maximize comparability between countries I Share of people fully vaccinated against COVID-19 J Share of p
Slide 10: Competitive landscape
COVID-19._ Vaccine Commercial Analysis Competitive landscape * Most competitive vaccine market ever — 129 Marketed/clinical-stage vaccines * 45 Clinical-stage protein subunit vaccine candidates (same type as Terra CoV-2) * 9 Clinical-stage intranasal vaccines — 194 Preclinical-stage vaccine candidat
Slide 11: Intranasal vaccine pipeline is limited and earlier stage
COVID-19 Vaccine Commercial Analysis Intranasal vaccine pipeline is limited and earlier stage Clinical-stage Intranasal Vaccine Candidates vs. Oragenics’ Terra Cov-2 Aue an : : : Clinical Organization Organization Type Vaccine Candidate Vaccine Type Stage Precision Viralogics/ Us private biotech/ BB
Slide 12: Intranasal vaccine media coverage
COVID-19 vaccines: could a squirt up the nose be just as good as a shot in the arm? eral COVID-19 vaccines be need to be injected and March 2021 —by Priya Jol MEDPAGETODAY Can Intranasal COVID Vaccines Help Stop the Spread? — Its time for new approaches to fighting this virus by Daniel Teres, MO, an
Slide 13: Protein subunit vaccine pipeline
COVID-19 Vaccine Commercial Analysis Protein subunit vaccine pipeline Late-stage Protein Subunit Vaccine Candidates vs. Oragenics’ Terra Cov-2 Comp. Company Type Adjuvant Route Admin. Clinical Stage Madigan Taiwanese vaccine CpG 1018 Intramuscular (IM) EUA : : 7 9 manufacturer (Dynavax) injection (T
Slide 14: COVID-19 Vaccine Commercial Summary
COVID-19 Vaccine Commercial Summary Terra CoV-2 commercial opportunity * Focus on intranasal Terra CoV-2 candidate — Less competition and more opportunities to differentiate * Establish first as preferred booster dose — Reduce virus transmission at source of infection (mucosal surfaces) — Needle-fre
Slide 15: Slide 15
Slide 16: Terra CoV-2 vaccine development partnership
(. wu sequence * 2P substitution + Licensed to y Pfizer/BioNTech, A Moderna + IgA (mucosal) AbN " * IgG (systemic) Ab + BDX adjuvant family \_ has clinical record + Sequence -> Stable Cell Line in 6-8 wks + Platform mfg \ process y . Closely Aligned with NRC + Small agile CDMO + Phase 1 program _) s
Slide 17: Vaccine Program CMC Updates
Vaccine.Program CMC Updates Activity Status "National Research Coun of Canad (censor of CllLine @¢Pistform) Important partner to Oragenics/Biodextris Supporting R&D activities to de-risk development and critical path activities + Areas of program support Process -> Methods -> Characterization -> Cel
Slide 18: Corporate Status Update
Corporate Status Update
Slide 19: Capitalization
Capitalization Common Stock Equivalents Common Stock Outstanding 116,394,806 Cash $30.0M « “ as . Series A and Series B Convertible Preferred (As Converted) 2:261,703 Warrants (WAEP $1.42) 18,040,572 Reserved for issuance under 8,009,250 stock incentive plan Total 144,706,331 The Information is as o
Slide 20: Company Summary
Company Summary + SARS-CoV-2 spike protein vaccine technology licensed from NIH expected to enter human clinical studies in 2022; potential long-lasting protection against SARS-CoV-2, new variants and perhaps other coronaviruses + NRC's swift expression platform in combination with NIH constructs ac
Slide 21: For More Information
For More Information | Corporate N Investors: Michael Sullivan \ Kim Golodetz, Senior Vice President, Princi “Chief ncial Officer ~~ LHA Investor Relations: Results that Mi 813.286.7900 ext. 246 \ T: 212.838.3777 | KGolodetz@lhai msullivan@oragenics.com